CytoMed Therapeutics Limited (NASDAQ:GDTC) Stock Short Interest Declines 43.2%

CytoMed Therapeutics Limited (NASDAQ:GDTC) saw a large decline in short interest in September. As of September 15th, there was short interest totaling 3,620 shares, a decline of 43.2% from the August 31st total of 6,370 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 11,046 shares, the short-interest ratio is presently 0.3 days.

CytoMed Therapeutics Stock Performance

GDTC traded down $0.02 during midday trading on Thursday, hitting $0.82. 357 shares of the company traded hands, compared to its average volume of 224,490. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17. The company’s 50-day moving average is $0.90 and its 200 day moving average is $0.98. CytoMed Therapeutics has a 52 week low of $0.68 and a 52 week high of $3.68.

CytoMed Therapeutics (NASDAQ:GDTC) last announced its quarterly earnings results on Wednesday, September 30th. The company reported ($0.06) EPS for the quarter. The firm had revenue of $0.06 million for the quarter.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GDTC. Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research note on Wednesday, July 8th. Fundamental Research set a $4.16 price target on shares of CytoMed Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CytoMed Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.16.

About CytoMed Therapeutics

CytoMed Therapeutics Limited is a Singapore-based clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research centers on using immune cells to recognize and attack tumor cells, with an emphasis on developing treatments that may be suitable for broader use than certain patient-specific therapies.

CytoMed is developing a pipeline of investigational therapies based on technologies involving gamma delta T cells, natural killer T cells and other immune-cell platforms.